Pfizer Inc. today announced that the REFLECTIONS B7391003 study — a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab) — met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
Discovery Worldwide, a healthcare communications agency that combines the power of science, storytelling and innovative delivery to move health forward, announced the appointment of Rico Ricketson as Head of Client Services.
Klick Health announced it is expanding its Behavioral Science team as part of its extensive lineup of in-house, full-service healthcare marketing and commercialization capabilities.
The Medical Advertising Hall of Fame will be holding its first Midwest event on Sept. 21, 2017, at the offices of the Sandbox Agency in Chicago.
UDG Healthcare plc announced the acquisition of Cambridge BioMarketing LLC, a U.S.-based healthcare communications business, for a total consideration of up to $35 million.
Fingerpaint, a full-service marketing agency with offices in Arizona, Pennsylvania, New York and Ohio, named a longtime creative duo as the new leaders of the agency’s creative team. Katie Beller and Andy Spitzer will be based in the agency’s headquarters in Saratoga Springs, New York.
For the first time, EPGL reveals the “Omega” contact lens under development with InWith Corp. The patent pending “Omega” is designed to correct vision anytime by changing the curvature of the lenses on-demand, via smart phone or other mobile devices.
The National Pharmaceutical Council will host a webinar, “Same Condition, Different Costs: Should Patients Pay Different Amounts?” to discuss the practical realities of different cost-sharing models for prescription drugs.
From the leaders of marketing teams to medical affairs, pharma executives are increasingly required to do more with less. While this is true across industries, the U.S. biopharma industry is faced with unique headwinds.
